AYTU BIOPHARMA, INC. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by AYTU BIOSCIENCE, INC. (also referred to as AYTU BIOPHARMA, INC.) on April 18, 2017, reporting events occurring on April 14, 2017. The filing addresses Item 5.02 regarding the appointment of certain officers and their compensatory arrangements.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on executive compensation agreements.
Material Changes and Executive Compensation
On April 14, 2017, the company entered into new two-year employment agreements with Joshua R. Disbrow (CEO and Chairman) and Jarrett T. Disbrow (COO), effective April 16, 2017. Key terms include:
- Base Salary: $250,000 annually for each officer.
- Performance Bonus: Discretionary bonus with a target of 125% of base salary.
- Stock Options: To be granted on or after August 1, 2017. The number of shares will be at least equal to the highest amount issued to any other employee. Vesting schedule: 50% on grant date, 25% after 365 days, and 25% after 730 days.
- Severance: In the event of termination without Cause or resignation for Good Reason, the company must pay accrued compensation plus a lump sum equal to two times the base salary, along with up to two years of health benefits.
- Change in Control: All stock options and restricted stock will immediately vest upon a Change in Control.
Guidance, Risks, and Contingencies
The filing does not contain financial guidance or general business outlook. The primary contingency described relates to the definitions of "Cause" and "Good Reason" which trigger specific severance obligations and option vesting accelerations. "Good Reason" includes material reductions in compensation (below $250,000), responsibilities, or a material change in geographic location (outside 40 miles of Denver).
Investor Verification Checklist
- Verify the exact number of stock options to be granted to the executives on or after August 1, 2017, as the specific quantity is not disclosed in this summary.
- Review the full text of Exhibits 10.1 and 10.2 for complete legal definitions of "Cause," "Good Reason," and "Change in Control."
- Confirm the company's current cash position to assess its ability to fund potential severance payments (2x base salary) if terminations occur.
- Check subsequent filings to confirm the grant date and exercise price of the stock options mentioned.